Contraline Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Contraline's estimated annual revenue is currently $4.2M per year.(i)
  • Contraline's estimated revenue per employee is $155,000

Employee Data

  • Contraline has 27 Employees.(i)
  • Contraline grew their employee count by 80% last year.

Contraline's People

NameTitleEmail/Phone
1
Chief Technology OfficerReveal Email/Phone
2
VP QualityReveal Email/Phone
3
Director Finance and Business DevelopmentReveal Email/Phone
4
Director ResearchReveal Email/Phone
5
Associate Manager, Preclinical StudiesReveal Email/Phone
6
Project ManagerReveal Email/Phone
7
Operations/HR/Finance ManagerReveal Email/Phone
8
Operations ManagerReveal Email/Phone
9
Associate Manager Clinical OperationsReveal Email/Phone
10
Product Development ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3M393%$28.3MN/A
#2
$1.4M9-18%N/AN/A
#3
$5.3M343%N/AN/A
#4
$31.9M2060%N/AN/A
#5
$0.6M4-43%N/AN/A
#6
$4.3M55-52%$56.5MN/A
#7
$0.3M20%N/AN/A
#8
$5.4M3521%N/AN/A
#9
$1.9M120%N/AN/A
#10
$2.6M34-11%$9.8MN/A
Add Company

What Is Contraline?

Contraline is a medical device company developing a long-lasting, non-hormonal, and reversible male contraceptive using advancements in hydrogel technology.

keywords:N/A

N/A

Total Funding

27

Number of Employees

$4.2M

Revenue (est)

80%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Contraline News

2022-03-30 - Contraline Appoints Medical Device Industry Leader Dr ...

... joins Contraline as Chief Technology Officer; Dr. Tropsha will spearhead efforts to bring Contraline's male contraceptive device, ADAM™,...

2022-03-22 - Male Birth Control Explained As New Pill 99 Percent Effective in Mice

ADAM is a birth control method being investigated by medical device company Contraline. It would work by injecting a gel into the vas...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.7M27-13%N/A
#2
$3.9M2840%N/A
#3
$4M28155%N/A
#4
$5.3M28-12%$58M
#5
$5.3M288%N/A